Armour Thyroid Slow Titration for Sensitivity: A Clinical Guide

What Makes Armour Thyroid Different from Levothyroxine?

Armour Thyroid is a porcine-derived desiccated thyroid extract. Each grain (60 mg) contains approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3), yielding a T4:T3 mass ratio of roughly 4.22:1 [1]. Synthetic levothyroxine contains no T3 at all.

That T3 content is why Armour Thyroid behaves differently in sensitive patients. T3 is three to five times more biologically active than T4 on a per-microgram basis and acts within hours rather than days [2]. Patients who have impaired T4-to-T3 conversion due to DIO2 polymorphisms or other factors may respond more strongly to the added T3 than expected, making gradual escalation non-negotiable.

The Hoang 2013 RCT: Head-to-Head Evidence

The most-cited comparative trial is Hoang et al. (J Clin Endocrinol Metab, 2013, N=70), which randomized hypothyroid patients on stable levothyroxine to either continue levothyroxine or switch to desiccated thyroid extract for 16 weeks [3]. The NDT group showed a mean 3.1-pound greater weight loss and higher rates of patient preference (48.6% preferred NDT vs. 18.6% preferring levothyroxine, P<0.001). Neurocognitive scores did not differ significantly between groups, but patients on NDT reported better quality-of-life scores on several subscales.

What the FDA Label Says About Dosing

The Armour Thyroid prescribing information approved by the FDA specifies starting at 30 mg daily for typical adult hypothyroid patients, with increases of 15 mg every two to three weeks [1]. For patients described as having cardiovascular disease or heightened sensitivity, the label explicitly recommends a lower starting dose and slower titration intervals. The label does not define a maximum dose but notes that most patients are maintained between 60 mg and 120 mg daily.

Sensitive patients often need to start below the label's standard 30 mg, with 15 mg being the practical floor for most clinicians.

Why Slow Titration Matters for Sensitive Patients

A slow titration schedule reduces the risk of adrenergic side effects: palpitations, anxiety, heat intolerance, and insomnia. These effects are primarily driven by the T3 fraction, which peaks in serum roughly two to four hours after an oral dose [4].

Who Qualifies as "Sensitive"?

Patients who may need a slower-than-standard protocol include those with:

• Prior adverse reactions to any thyroid hormone preparation
• Adrenal insufficiency or low cortisol on saliva/serum testing (adrenal fatigue in functional medicine contexts)
• Cardiovascular disease, arrhythmia history, or resting heart rate above 80 bpm at baseline
• Severe hypothyroidism of long duration (TSH above 50 mIU/L), where tissues may be highly responsive once hormone is reintroduced
• Body weight below 50 kg
• Age 65 or older, given the increased sensitivity to T3 in older adults documented in the endocrine literature [5]

The American Thyroid Association (ATA) 2014 guidelines note that "patients with cardiac disease or the elderly should be started at lower doses and titrated slowly," a principle that applies directly to NDT as well as to levothyroxine [6].

The Adrenal Connection

Some integrative and functional medicine clinicians argue that undiagnosed adrenal insufficiency predisposes patients to NDT intolerance. The reasoning: adequate cortisol is required for thyroid hormone to bind its nuclear receptors effectively. When cortisol is low, increasing T3 may trigger catecholamine-like symptoms. This hypothesis is physiologically plausible given the known interaction between the hypothalamic-pituitary-adrenal axis and thyroid hormone metabolism [7], although large RCTs testing the "adrenal support before NDT" strategy are lacking. Clinicians managing sensitive patients sometimes obtain an 8 AM serum cortisol or a 24-hour urine cortisol before starting NDT.

The Slow Titration Protocol: Step by Step

The protocol below reflects published clinical experience and the FDA label parameters adapted for sensitivity [1, 3, 8].

Step 1: Pre-Treatment Baseline Labs

Before prescribing Armour Thyroid, obtain:

• TSH (ultrasensitive), free T4, free T3
• Complete metabolic panel and CBC
• Resting heart rate and blood pressure
• Morning serum cortisol if adrenal concerns exist
• Lipid panel (hypothyroidism raises LDL cholesterol, and normalization confirms adequate dosing over time) [9]

Baseline free T3 below the lower reference limit (<2.3 pg/mL in most assays) with a normal or high TSH confirms the clinical picture of primary hypothyroidism with poor conversion, a common reason patients and clinicians choose NDT over levothyroxine alone.

Step 2: Starting Dose

Most sensitive patients begin at 15 mg once daily taken on an empty stomach 30 to 60 minutes before breakfast, or at least three to four hours after the last meal. Food, particularly high-fiber or calcium-rich foods, reduces absorption by as much as 30% [1].

Some very sensitive patients (resting heart rate above 80 bpm, prior palpitations on thyroid medication, or severe anxiety disorders) start at 7.5 mg. The 15 mg tablet can be split; Armour Thyroid tablets are scored for this purpose.

Step 3: First Reassessment at Four to Six Weeks

Recheck TSH, free T4, and free T3 four to six weeks after starting. At steady state, serum T3 peaks within the first few hours post-dose, so labs drawn in a fasting state before the morning dose give the most reproducible trough values [10]. If the patient reports no palpitations, resting heart rate stays below 85 bpm, and labs show TSH still above the upper target, increase by 15 mg.

Step 4: Escalation Increments

Increase by 15 mg every four to six weeks. For highly sensitive patients, 7.5 mg increments are reasonable, though tablet splitting introduces minor dosing variability.

The table below outlines a representative slow-titration schedule:

| Week | Dose | Action | |------|------|--------| | 1 to 4 | 15 mg/day | Observe; check resting HR daily | | 5 to 6 | Labs drawn | Adjust if TSH still elevated and no symptoms | | 6 to 10 | 30 mg/day | Second hold; monitor HR and sleep | | 11 to 12 | Labs drawn | Adjust based on labs and symptoms | | 13 to 17 | 45 mg/day | Continue hold | | 18 to 19 | Labs drawn | Many sensitive patients reach target here | | 20 to 24 | 60 mg/day | Most patients in therapeutic range |

Escalation pauses permanently if TSH falls below 0.5 mIU/L or if free T3 exceeds the upper reference range (>4.2 pg/mL in most US lab assays) [6].

Step 5: Recognizing Overshoot

Signs of over-replacement with NDT include:

• Resting heart rate consistently above 90 bpm
• Palpitations or irregular heartbeat
• Unexplained weight loss exceeding 0.5 kg/week
• Drenching night sweats or heat intolerance
• TSH below 0.1 mIU/L with free T3 above the reference range

If any of these appear, reduce the dose by one increment (15 mg) and recheck labs in three weeks. Do not stop abruptly; sudden withdrawal can trigger a hypothyroid rebound with significant fatigue and cognitive slowing.

Lab Targets During Armour Thyroid Titration

Lab interpretation on NDT differs from interpretation on levothyroxine because the T3 content partially suppresses TSH at doses that do not produce clinical thyrotoxicosis.

TSH: A Moving Target on NDT

Several studies and clinical series report that patients on NDT often have TSH values in the low-normal to mildly suppressed range (0.1 to 1.0 mIU/L) while feeling well and showing no signs of over-replacement [3, 11]. The ATA 2014 guidelines state that "a normal TSH does not guarantee a euthyroid state in all tissues," acknowledging the complexity of monitoring combination T4/T3 therapy [6].

For sensitive patients on slow titration, targeting a TSH between 0.5 and 2.0 mIU/L during escalation is a practical approach. Once the patient is stable, some clinicians accept TSH values as low as 0.3 mIU/L if free T3 remains within the upper half of the reference range and symptoms are resolved.

Free T3: The Functional Marker

Free T3 is a more direct measure of active hormone exposure than TSH on combination therapy. A meta-analysis of 14 trials (N=1,216) examining hypothyroid patients on T4 plus T3 versus T4 alone found that free T3 levels tracked symptom improvement more closely than TSH did [12]. Target free T3 in the upper half of the reference range (roughly 3.0 to 4.2 pg/mL) during stable maintenance.

Draw labs as a trough: before the morning dose, in a fasting state. Post-dose T3 peaks cause a transient elevation that does not reflect the day-long average and may lead to unnecessary dose reductions [10].

Free T4: Expected to Run Low

Because Armour Thyroid delivers less T4 per grain than a comparable levothyroxine dose would, patients on NDT routinely show free T4 in the lower half of the reference range or just below it. This is expected and not a sign of under-replacement as long as free T3 and TSH are on target [3].

Dosing Considerations Specific to Sensitive Populations

Elderly Patients (Age 65 and Older)

Cardiac sensitivity to T3 increases with age. A retrospective cohort study of thyroid hormone users over 65 found that over-replacement (suppressed TSH) was associated with a 1.88-fold higher risk of atrial fibrillation (HR 1.88, 95% CI 1.63 to 2.16) compared to euthyroid controls [13]. Older patients on NDT should not exceed a TSH target below 1.0 mIU/L during maintenance, and escalation steps should stay at six-week intervals.

Patients with Cardiovascular Disease

The FDA label explicitly warns against use in patients with acute myocardial infarction uncomplicated by hypothyroidism [1]. For stable coronary artery disease or controlled heart failure, NDT is not absolutely contraindicated, but the slow-titration approach is mandatory. The cardiovascular literature recommends maintaining TSH between 1.0 and 2.5 mIU/L in this group [14].

Patients Converting from Levothyroxine

A common conversion ratio is 100 mcg levothyroxine equivalent to approximately 60 mg (one grain) of Armour Thyroid, based on T4 content equivalence [1]. However, sensitive patients converting from levothyroxine should not make a full one-for-one switch on day one. A safer approach:

1. Reduce the levothyroxine dose by 50%.
2. Add 15 mg Armour Thyroid simultaneously.
3. After four weeks with no adverse symptoms, discontinue the remaining levothyroxine and increase Armour Thyroid by 15 mg.
4. Continue the standard slow-titration schedule from that point.

This cross-taper limits the abrupt T3 increase that a full switch would produce.

Practical Administration Tips

Taking Armour Thyroid Correctly

Armour Thyroid tablets should be taken on a fully empty stomach. The most consistent practice is first thing in the morning, 30 to 60 minutes before any food, coffee, or other medications [1]. Calcium carbonate, iron supplements, magnesium, cholestyramine, and proton pump inhibitors all impair absorption and should be separated by at least four hours [15].

Some patients with gastrointestinal sensitivity report less nausea when the tablet is placed under the tongue (sublingual administration). Absorption via the sublingual route has been described in case reports and small series, but no large pharmacokinetic trial has validated this route for NDT specifically [16].

Split Dosing

The short half-life of T3 (approximately 19 hours) means some patients experience a mid-afternoon energy dip attributable to falling T3 levels. Splitting the total daily dose into two administrations, roughly 70% in the morning and 30% at noon, can smooth this curve [4]. This strategy is worth considering once the total daily dose reaches 60 mg or higher. Doses taken in the evening may impair sleep in sensitive patients.

Biotin Interference

Biotin (vitamin B7) supplements at doses of 5,000 mcg or more interfere with the immunoassay used for TSH, free T4, and free T3 measurements, producing falsely low TSH and falsely elevated free thyroid hormone values. The FDA issued a safety communication on this interference in 2017 [17]. Patients should stop all biotin supplements at least 48 hours before any thyroid labs.

Monitoring Schedule During the Full Titration Course

The following framework reflects the clinical approach used by the HealthRX medical team for NDT slow titration, synthesizing FDA label guidance, the Hoang 2013 trial protocol, and ATA monitoring recommendations:

Phase 1 (Weeks 1 to 12): Initiation and early escalation

• Labs every four to six weeks: TSH, free T4, free T3
• Patient check-in by message or call at two weeks after each dose change
• Resting heart rate log kept by patient (wearable or manual)

Phase 2 (Weeks 13 to 24): Optimization

• Labs every six weeks until two consecutive stable results
• Blood pressure check at each visit
• Symptom questionnaire (fatigue, hair loss, cold intolerance, cognitive speed) scored 0 to 10

Phase 3 (Maintenance): Stable dosing

• Labs every six months: TSH, free T4, free T3
• Annual lipid panel to confirm metabolic normalization
• Bone density screening per USPSTF guidelines if TSH remains below 0.5 mIU/L long-term [18]

Patients with stable TSH within the target range for at least 12 months and no symptoms may extend monitoring to annual labs, consistent with ATA recommendations for stable hypothyroid patients on thyroid hormone replacement [6].

How Quickly Can You Increase Armour Thyroid?

The fastest evidence-based escalation schedule from the FDA label allows increases of 15 mg every two weeks in otherwise healthy adults [1]. Most clinicians managing sensitive patients use four-week minimum intervals. Shorter intervals risk accumulating adverse T3 effects before the prior increment has reached full physiological steady state (T3 half-life approximately 19 hours, but tissue equilibration takes five to seven days) [4].

Increasing more frequently than every two weeks in any patient is outside FDA label guidance and is not supported by published trial data.